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Abstract 
Recent trials have demonstrated that onabotulinumtoxinA is a safe and effective 
treatment for the prevention of chronic migraine headaches. Although the exact effect of the 
toxin on the pathophysiology of migraine is not clear, several in-vivo and in-vitro models have 
shown that onabotulinumtoxinA inhibits the release of neurotransmitters and neuropeptides 
involved in pain signaling pathways with resulting attenuation of both peripheral and central 
sensitization in migraine.  Limited systemic adverse effects and physician administered 
treatments that eliminate concerns for patient compliance have made onabotulinumtoxin A an 
appealing alternative to oral prophylactic medications for migraine. This article is designed to 
provide an overview of current research into the mechanism of action of onabotulinumtoxinA in 
the pathophysiology of pain conditions including migraine, as well the current literature 
supporting its efficacy in migraine treatment. 
In the 1820s, Justinus Kerner described the clinical syndrome of botulism as a foodborne 
illness after compiling 76 cases of lethal food poisoning that occurred following the ingestion of 
spoiled smoked sausages
1
. He isolated an extract that contained the purported toxin from the 
sausages and characterized its effects on animal models. His published reports proposed that the 
isolated toxin had potential therapeutic uses
1. Kerner’s ideas, though visionary, were not fully 
realized until the late 1970s, when ophthalmologist Alan Scott used onabotulinumtoxinA for the 
treatment of strabismus and blepharospasm
2
. 
Today, onabotulinumtoxinA (BoNT-A) is used in the management of several medical 
conditions, including dystonia, blepharospasm, and spasticity, and is the only FDA-approved 
medication for the prevention of chronic migraines. The observation of therapeutic benefit of 
BONT-A in the treatment of pain has incited research into the mechanism of action of BoNT-A 
outside of the neuromuscular junction. Although the pathophysiology is still not well understood, 
the use of BoNT-A in the prevention of chronic headaches, specifically chronic migraine, has 
proven to be an effective treatment modality, with few contraindications and minimal side 
effects.  
Effect of Onabotulinumtoxin A on Cholinergic Neurons 
The effect of BoNT-A on the neuromuscular junction is well described. When injected 
into the target muscle, the C-terminal of the heavy chain binds to ganglioside acceptor protein on 
the plasma membrane of the alpha motor neuron and mediates endocytosis of the toxin
3
. The 
acidic environment within the vesicle leads to conformational change of the toxin, and reduction 
of the linking disulfide bond separates heavy chain and light chain. The light chain is 
translocated from the endocytotic vesicle into the neuronal cytosol. Within the cytosol, the light 
chain acts as a zinc endopeptidase and cleaves vesicular docking protein SNAP-25, a component 
of the SNARE complex that facilitates fusion of the membrane of the acetylcholine (ACh)-
containing vesicle with the presynaptic membrane.  The various botulinum toxins target different 
proteins in the SNARE complex.  Toxins A/E/C target SNAP-25, B/D/F/G target VAMP (aka 
synaptobrevin), C also targets syntaxin.  Cleavage of SNAP-25 inhibits Ach vesicle docking on 
the presynaptic membrane and inhibits ACh release into the neuromuscular junction. This results 
in partial chemical denervation and subsequent reduction in muscle activity. Recovery from 
chemical denervation involves sprouting of new nerve terminal and resumption of synaptic 
activity in the original terminal
4
. In clinical use of onabotulinumtoxinA in humans, this takes 2-6 
months
5
.  
As the clinical use of BoNT-A increased following Dr. Scott’s work in strabismus, 
providers made a number of curious observations about the effects of the medication after it was 
injected for involuntary movements. Reports included descriptions of bilateral and distant effects 
after unilateral injection for spasticity and dystonia, decrease in muscle spasm strength and 
muscle spasm frequency, and alleviation of sensory symptoms, such as neck tenderness in 
spasmodic torticollis and light sensitivity in blepharospasm
6
. Giladi cites a number of examples 
where the improvements in sensory symptoms were disproportionate to the degree of muscle 
weakness or outlasted the duration of muscle weakness
6
. These observations suggested that 
BoNT-A had effects in addition to those on motor neurons. 
A possible explanation for the effect on neurons distal to the injection site was proposed 
after it was shown that onabotulinumtoxinA undergoes retrograde transport in motor neurons
7
. 
Antonucci et al. demonstrated BoNT-A truncated SNAP-25 at distal projections from both 
peripheral and central BoNT-A injections. The transport of SNAP-25 was inhibited by 
colchicine, indicating microtubule-dependent axonal transport. BoNT-A also inhibits gamma-
motor neurons innervating intrafusal fibers in muscle spindles
8
.  Information about muscle 
stretch is transmitted from muscle spindles to the CNS via 1a afferents. It has been proposed 
there is some degree of pain relief from the resulting reduction in afferent input of tonic muscle 
contractions
9
. However, it is difficult to extrapolate this hypothesis to the mechanism of action of 
BoNT-A on headache because facial muscles contain very few muscle spindles
6
.  
BoNT-A inhibits cholinergic neurotransmission in the autonomic nervous system. 
Several neurotransmitters and neuropeptides, including enkephalins, substance P, neurotensin, 
somatostatin, ATP, vasoactive intestinal protein (VIP) , neuropeptide Y, and NO, co-localize 
with ACh in autonomic neurons
10,11
. BoNT-A may inhibit the release of substances other than 
ACh that are released through a common vesicular docking mechanism
12
. Some authors also 
postulate that the inhibition of autonomic transmission by BoNT-A may suppress neurogenic 
inflammation
11
. 
The potential of BoNT-A in the treatment of migraine was first reported by Binder et al 
in 2000, after observations that patients treated for hyperfunctional facial lines reported 
alleviation of migraine symptoms
5
.  The effect was unexpected and prompted further research 
into the pathophysiology of BoNT-A in the transmission of pain-signaling pathways. 
Effect of Onabotulinumtoxin A on Afferent Neurons 
Several in vivo and in vitro studies have demonstrated that BoNT-A inhibits the release 
of neurotransmitters and neuropeptides involved in inflammatory pain such as glutamate
13
, 
substance P
14, 15
, and CGRP
16
.  A rat model for inflammatory pain with the injection of formalin 
solution into the hindpaw results in characteristic behaviors associated with pain, such a licking 
the injected paw. The typical behavioral response is biphasic, with an early response evoked by 
peripheral sensitization of nociceptors, followed by decrease in pain-associated behaviors 
attributed to descending inhibition, and finally a recurrence of pain-associated behaviors that 
reflect the development of peripheral inflammation and central sensitization. Peripheral injection 
of BoNT-A reduced the second phase of formalin-induced nociceptive behavior in a dose 
dependent manner
13
.  BoNT-A also resulted in dose-dependent reduction in mechanical allodynia 
and thermal hyperalgesia in an animal model of peripheral neuropathic pain
17
.   
  The effect of BoNT-A on migraine is postulated to involve inhibition of both peripheral 
and central sensitization. A rat model of migraine via sensitization of dorsal horn neurons in the 
trigeminal nucleus caudalis showed that chemical irritation of the dura results in a 2- to 3-fold 
increase in extracellular glutamate.  However, there was no significant change in extracellular 
glutamate in rats pre-treated with periorbital injection of BoNT-A
18
.  In a rat model of trigeminal 
neuropathy due to infraorbital nerve constriction, Kitamura et al demonstrated that BoNT-A 
resulted in reduction of both exaggerated neurotransmitter release in from trigeminal ganglia 
neurons and pain-associated behavior
19
.  Matak et al. recently demonstrated that BoNT-A 
truncated SNAP-25 in the trigeminal nucleus caudalis after peripheral injection, suggesting 
retrograde axonal transport of BoNT-A analogous to that described in alpha motor neurons. The 
antinociceptive effect of peripherally injected BoNT-A was inhibited by colchicine, suggesting 
that retrograde axonal transport and central action are obligate parts of the mechanism of action 
of BoNT-A on pain sensation
20
. 
BoNT-A inhibits peripheral sensitization by blocking the release of pain-related 
neurotransmitters and neuropeptides from peripheral nerve endings. The resulting reduction of 
afferent input into the CNS indirectly inhibits central sensitization. Additionally, BoNT-A 
undergoes retrograde transport into central trigeminal neurons and has been shown to decrease 
centrally mediated neurotransmitter release, which directly inhibits central sensitization.  
 Clinical Results of OnabotulinumtoxinA in the Prevention of Episodic Migraine 
Although initial results on the use of BoNT-A in the treatment of episodic migraine were 
positive, subsequent trials failed to show a significant improvement in migraine frequency or 
severity. In the first study following Binder and colleagues’ initial observations, 123 subjects 
with 2 to 8 migraines/month were randomized to placebo, 25U, or 75U BoNT-A. Injections sites 
included bilateral frontalis, temporalis, procerus, and corrugator muscles. There was a significant 
decrease in migraines/month in the 25U but not the 75U group, compared with placebo. The lack 
of effect in the higher-dose group was attributed to lower mean migraine frequency in the 
baseline group characteristics; 4.3 in the 25U group compared with 4.0 in the 75U group
21
. 
Subsequently, Evers et al evaluated differences in response to frontal versus neck muscle 
injection sites. Sixty-six subjects with 2 to 8 migraines/month were randomized to either 100U in 
the frontalis, temporalis, SCM, trapezius, splenius capitus, and semispinalis, or 16U in the 
frontalis and temporalis and placebo in the neck muscles, or placebo in all muscle groups. There 
was no significant difference in migraine frequency among the three treatment groups. However, 
there was a significant decrease in migraine-associated symptoms in the 16U, but not the 100U, 
treatment group
22
.   
Elkind et al evaluated 418 subjects with 4 to 8 migraines/month in three sequential four 
month trials with re-randomization at each stage. Subjects were treated with 7.5U, 25U, or 50U 
BoNTA. There were no significant differences in migraine frequency between the two groups
23
.   
Aurora et al evaluated the “follow-the-pain” injection protocol in episodic migraine. 
Fixed-dose injections were given in the occipitalis, with the remainder of the injections and 
doses chosen based on the severity and distribution of the subject’s pain rather than fixed doses 
in predetermined muscles (the “fixed-site, fixed-dose” paradigm). The study randomized 369 
subjects with ≥ 4 migraines but ≤ 15 headache days/month to three treatments with 110 to 260U 
BoNTA or placebo every 90 days. There was no statistically significant difference between the 
two groups. However, subgroup analysis of subjects with a baseline migraine frequency of  ≥ 12 
headache days/month did show a significant decrease in headache episodes compared with 
placebo at the Day 180 endpoint, -4 versus -1.9 (p=0.48)
24
.  
In an effort to better characterize BoNTA responders with episodic migraine, Relja et al 
divided subjects into placebo responders (n=173) and placebo nonresponders (n=322) and then 
randomized to 75, 150 or 225U BoNTA or placebo every 90 days for 6 months. Subjects on 
concomitant preventive migraine medications were excluded. Injections were fixed-site, fixed-
dose into the frontalis, corrugator, temporalis, trapezius, splenius capitus, semispinalis, and 
occipitalis muscles. There was no significant difference in headache frequency between the two 
groups at the Day 180 primary endpoint
25
. 
Saper et al evaluated the effect of different injection sites and dosing amounts in 232 
subjects with 4 to 8 migraines/month. Subjects were randomized to four different injection site 
patterns: frontalis (10U), temporalis (6U), glabellar (9U), or all three sites combined (25U). 
There was no significant difference in headache frequency at the Day 60 primary endpoint
26
. The 
authors supposed that one of the reasons for the negative results may have been due to the low 
doses of BoNT-A. 
Clinical Results of OnabotulinumtoxinA in the Prevention of Chronic Daily Headache and 
Chronic Migraine  
While the aforementioned authors were evaluating the efficacy of BoNT-A in episodic 
migraine, Mathew et al. reported a positive outcome in a heterogeneous patient population with 
chronic daily headache (CDH)
27
. CDH is a broad category that includes any primary headache 
disorder that occurs with a frequency of 15 days/month or more. In this randomized, double-
blind, placebo- controlled trial, 355 subjects with headache ≥ 15 days/month were divided into 
placebo responders (n=76) and nonresponders (n=279) and treated with 105 to 260U in a 
“follow-the-pain” distribution every 90 days for three treatment cycles. Although there was no 
significant difference for the primary endpoint of the number of headache-free days at Day 180, 
there were significant differences in several secondary endpoints. The BoNTA treatment group 
had a larger percentage of subjects with a ≥50% reduction in headache frequency and a greater 
mean change from baseline headache frequency at Day 180
27
. A subgroup analysis that excluded 
subjects taking preventive migraine medication found that the BoNTA treatment group had a 
statistically significant decrease in headache frequency compared to placebo after the second and 
third treatments
28
. A similar randomized, placebo controlled trial by Silberstein et al that 
evaluated 702 subjects with CDH did not meet the primary endpoint of mean reduction in 
headache frequency at Day 180
29
. However, subjects receiving 150U and 225U of BoNT-A had 
a greater decrease in headache frequency at day 240 that those taking placebo. These results, 
combined with Aurora et al’s significant difference in subgroup analysis of migraine patients 
experiencing ≥ 12 headache days/month24, prompted further investigation into the efficacy of 
BoNT-A in chronic migraine (CM).  
The PREEMPT clinical program confirmed the efficacy and safety of BoNT-A in the 
preventive treatment of adults with CM. Two phase-3, multicenter studies (PREEMPT 1 and 
PREEMPT 2), which each had a 24-week, double-blind, parallel-group, placebo-controlled phase 
followed by a 32-week open-label phase, enrolled 1384 patients with CM. All patients received 
the minimum dose of 155 U of BoNT-A administered to 31 injection sites across seven head and 
neck muscles using the fixed-site, fixed-dose injection paradigm. A modified follow-the-pain 
approach with ≥ 40 U BoNT-A, administered to eight injection sites across three head and neck 
muscles, was also allowed. There were statistically significant reductions from baseline for 
frequency of headache days after BoNT-A treatment compared with placebo treatment in both 
PREEMPT 1 and PREEMPT 2 (P = 0.006; P < 0.001). There was also statistically significant 
improvement from baseline headache frequency after BoNTA treatment compared with placebo 
treatment in PREEMPT 2 (P = 0.003). Pooled analysis demonstrated that BoNT-A treatment 
significantly reduced mean frequency of headache days (−8.4 BoNT-A, −6.6 placebo; P < 0.001) 
and episodes (5.2 BoNT-A, −4.9 placebo; P = 0.009). Additionally, significant between-group 
differences favoring BoNT-A existed for several other secondary endpoints including migraine 
episodes, migraine days, moderate or severe headache days, cumulative hours of headache on 
headache days, and proportion of patients with severe disability. The PREEMPT results showed 
significant improvements in multiple headache symptom measures and demonstrated 
improvement in patients’ level of functioning, psychological distress, and overall quality of life. 
Multiple treatments of 155 U up to 195 U per treatment cycle administered every 12 weeks were 
shown to be safe and well tolerated
30, 31, 32
. 
Comparative Efficacy of OnabotulinumtoxinA in Chronic Migraine 
A few trials have been conducted that compared the effectiveness of BoNT-A to oral 
medication in migraine headache prevention . Mathew et al randomized 60 CM patients to either 
BoNT-A (100U fixed-site and 100 U follow-the-pain) and oral placebo or topiramate and 
placebo injections. Subjects received two rounds of injections at study start and month 3, 
whereas the topiramate group continued medication until study completion at 9 months. Only 36 
subjects completed the study: 24.1% in the topiramate group dropped out due to adverse effect 
compared with 7.7% in the BoNT-A group. At the 9 month endpoint, a similar number of 
patients reported a ≥50% decrease in headache/migraines days in the BoNT-A and topiramate 
groups, 40.9% and 42.9% respectively
33
. Cady et al also evaluated BoNT-A to topiramate in a 
randomized, double-blind, placebo-controlled study of 59 CM patients over 12 weeks
34
. There 
was significant reduction in the number of headache days per month within but not between the 
two groups. 
A trial of 59 patients randomized to 100U BoNT-A and oral placebo or 250mg 
divalproex sodium BID and placebo injections showed similar improvement in migraine 
disability and reduction in headache days. There were a greater percentage of adverse effects and 
discontinuation in the divalproex group
35
. Another study of CM patients showed that treatment 
with 250U BoNT-A had similar efficacy as 25mg or 50mg amitriptyline
36
. 
These studies suggest that BoNT-A has similar efficacy and a superior side effect profile 
compared to available oral medications for prevention of CM.  Physician-administered injections 
every three month also reduce concerns for compliance with a daily dosing regimen. 
Techniques for Onabotulinumtoxin-A Injection in the Prevention of Chronic Migraine  
 The injection protocols commonly used are: (1) the fixed-site, fixed-dose approach, 
which uses fixed, symmetrical injection sites and predetermined doses; (2) the follow-the-pain 
approach, which often employs asymmetrical injections and adjusts the sites and doses 
depending on where the patient feels pain and where the examiner can elicit pain and tenderness 
on palpation of the muscle; and (3) a combination approach, which uses injections at fixed 
frontal sites, supplemented with follow-the-pain injections (this approach typically uses higher 
doses of BoNT-A)
37
.  
The PREEMPT clinical trials used a modified follow-the-pain injection paradigm
30, 31
.  
OnabotulinumtoxinA (155 U) was administered as 31 fixed-site, fixed-dose injections across 
seven specific head and neck muscle areas using a sterile 1 ml Luer Lock syringe with a 30-
gauge 0.5 inch needle. OnabotulinumtoxinA is available in single-use 50U, 100U or 200U vials. 
The 100U vial is reconstituted with 2mL sterile saline and the 200U vials with 4mL sterile saline 
for a final concentration of 5U onabotulinumtoxinA per 0.1 mL. Each injection in the fixed-dose 
paradigm is 0.1 mL (5U). Up to 40 U of additional onabotulinumtoxinA can be administered, 
using a follow-the-pain strategy, into the temporalis, occipitalis, and/or trapezius muscles, with a 
maximum dose of 195 U administered to 39 sites (Figures 1-4). When deciding on dose and 
location of additional onabotulinumtoxinA, the location of the patient’s predominant pain and 
the severity of palpable muscle tenderness should be considered. Figure 1 lists recommended 
anatomical sites of injection for headache and the onabotulinumtoxinA (BOTOX®) dose per site 
used in the PREEMPT trials. The injections are typically administered every 12 weeks.   
The most commonly reported side effects following injection of onabotulinumtoxinA for 
the treatment of chronic migraine include neck pain (9%), headache (5%), eyelid ptosis (4%), 
migraine (4%), muscle weakness (4%) and muscle stiffness (4%)
38
. The safety of 
onabotulinumtoxinA has not been determined in women who are pregnant or lactating. It is 
currently FDA pregnancy category C. It is contraindicated in patients with neuromuscular 
disorders, such as myasthenia gravis. When used for indications other than CM, instances of 
systemic symptoms resembling botulism due to distant spread beyond the area of injection have 
been reported. For this reason, the FDA requires all botulinum toxin products to carry a boxed 
warning of distant spread of toxin effect
38
.  
Conclusion 
Clinical studies suggest that BoNT-A is a safe and effective treatment in the prevention 
of CM. A favorable side effect profile and dosing schedule make it an attractive alternative to 
available oral medications, which are limited by adverse effects and the potential for 
noncompliance with dosing regimens. Further research is needed to understand the mechanism 
of action of BoNT-A on the pathophysiology of CM and fully evaluate its potential in the 
treatment of primary headache disorders.  
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Figure 1: (A) The corrugator injection sites (bilateral) are above the medial superior edge of the 
orbital ridge (bony landmark). (B) The procerus site is above and midline to the medial superior 
aspect of the orbital ridge (bony landmark) of each eye. (Figures 1-4 reprinted with permission
39
) 
 
Figure 2: The frontalis injection sites (bilateral) are located just beneath the skin surface of the 
central and forehead regions.  
 
Figure 3: (A) The first injection site is located in the anterior aspect of the temporalis muscle. 
The second and fourth sites are within the medial aspect and the third site is located in the 
posterior aspect of this muscle. These injections should be repeated symmetrically on the 
contralateral side for a total of 8 injections. Additional injections can be distributed between the 
right and left temporalis muscles in areas of maximal tenderness and/or pain. (B) The 6 
occipitalis muscle injection sites are located superior to the supranuchal ridge on either side of 
the occipital protuberance. In the areas of maximal tenderness and/or pain, up to 2 additional 
injections can be distributed across the right and left occipitalis muscles. 
 
Figure 4:  (A) The first cervical paraspinal injection site is lateral to the midline and inferior to 
the occipital protuberance. The second site is lateral and superior to the first injection. These 
injections should be repeated symmetrically on the contralateral side for a total of 4 injections. 
(B) The first of the 3 trapezius muscle injection sites is located in the lateral aspect of the muscle. 
The second site is within the mid-portion of the muscle and the third site is within the superior 
aspect of the muscle. Symmetrical injections should be repeated on the contralateral side for a 
total of 6 injections. Up to 4 additional injections can be distributed between the right and left 
trapezius muscles, in the areas identified as having maximal tenderness. 
 
 
